Excellence is just the beginning.


French German Italian Portuguese Russian

Chronic Myelomonocytic Leukemia (CMML) — Clinical Trials

Treatment Study for Patients with Higher-Risk MDS, CMML or Low-Blast AML

A phase 3, randomized, controlled, open-label, clinical study of pevonedistat plus azacitidine versus single-agent azacitidine as first-line treatment for patients sith higher-risk myelodysplastic syndromes, CML or Low-Blast AML.

Treatment Study for Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase II part 2 expansion of oral rigosertib in combination with azacitidine in patients with myelodysplastic syndrome or acute myeloid leukemia.